Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adavosertib in BRCA1/2 Mutated Tumors (MATCH Subprotocol Z1I)
NCT04439227Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2017
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adavosertib in solid tumor, lymphoma and multiple myeloma (MM), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 3 years. Started Mar 2017; status: active, not recruiting.
02
Drugs
adavosertib
03
Conditions
solid tumorlymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT04439227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04439227.